Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 0.00 (0.00%)
Spread: 0.50 (0.029%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1,733.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK WINNERS & LOSERS: Oil Producers Benefit As Brent Surpasses USD60

Fri, 13th Feb 2015 11:32

LONDON (Alliance News) - The following stocks are amongst the biggest risers and fallers within the main London indices midday Friday.
-------
FTSE 100 WINNERS
-------
Tullow Oil, up 4.6%, BG Group, up 3.0%, BP, up 1.6%, and Royal Dutch Shell 'A', up 1.0%. The oil producers are trading higher as the price of Brent oil surpasses the USD60 a barrel mark for the first time since the end of December. Brent currently trades at USD60.13 a barrel.

GlaxoSmithKline, up 3.7%. The pharmaceutical giant is trading higher after UBS upgraded the stock to Buy from Sell.

Anglo American, up 2.9%. The miner reported an expected drop in underlying earnings in 2014 on the back of weaker commodity prices. The company also took a USD3.9 billion impairment charge, mainly related to its iron ore mine in Brazil, which led to a wider net loss. However, it maintained its dividend unchanged. According to Investec, the company's earnings-per-share of 173 cents per share beat consensus of 164 cents.
-------
FTSE 100 LOSERS
-------
Severn Trent, down 1.1%. The water utility company said it is on track to meet its expectations for the full year, though it does expect growth to moderate in the second half.

Rolls Royce, down 0.6%. The jet engine and power turbine company reported a drop in profit, hit by negative currency translation, reduced defence spending and world macroeconomic uncertainty. The company said its reported pretax profit for the year to the end of December was GBP67 million, a massive decline against the GBP1.7 billion reported a year earlier.
-------
FTSE 250 WINNERS
-------
Afren, up 7.1%, Premier Oil, up 4.8%, and Ophir Energy, up 2.9%, all benefiting from the higher oil price.

RPS Group, up 4.5%. The energy consultancy said it has acquired Texas-based Klotz Associates in a USD24.1 million all-cash deal. Klotz provides engineering, planning and environmental consultancy services. For the year to the end of December, Klotz reported a pretax profit of USD3.6 million on revenue of USD26.2 million, RPS said.
-------
FTSE 250 LOSERS
-------
TalkTalk Telecom Group, down 1.2%. Jefferies has cut the group to Underperform from Hold.
-------
AIM ALL-SHARE WINNERS
-------
Mariana Resources, up 27%. The company has continued to rise, having gained 85% on Thursday following strong test results at its Hot Maden prospect in Turkey.

Fitbug, up 20%. The health and fitness wearables and online services company said that it expects to post a wider full-year loss in line with its forecasts, as increased investment in the development of its products offset a near quintupling of product sales in its second half. Fitbug said its sales in the second half were GBP1.4 million, taking its full year sales to GBP2.34 million compared to just GBP749,000 in all of 2013. The stock is trading at 6.84 pence, compared to 0.35p as recently as mid-October.

Cluff Natural Resources, up 9.1%. The company said it has entered a memorandum of understanding with a unit of US oil services company Halliburton related to developing Cluff's underground coal gasification and southern North Sea assets in the UK.
-------
AIM ALL-SHARE LOSERS
-------
Aeorema Communications, off 24%. The company said it anticipates a stronger second half, after it posted a drop in pretax profit due to lower revenues in its first half. In the half year to end-December the live events agency posted a pretax profit of GBP101,316, more than halved from GBP225,941 a year before, as revenue fell to GBP1.7 million from GBP1.8 million.
-------
By Neil Thakrar; neilthakrar@alliancenews.com; @NeilThakrar1

Copyright 2015 Alliance News Limited. All Rights Reserved.

More News
12 Feb 2024 08:35

TOP NEWS: GSK's bepirovirsen receives US FDA fast track designation

(Alliance News) - GSK PLC on Monday said that the US health watchdog granted fast track designation for its bepirovirsen treatment for chronic hepatitis B.

Read more
12 Feb 2024 07:50

LONDON BRIEFING: Tritax Big Box, UK Commercial Property agree merger

(Alliance News) - Equities in London are called to open higher on Monday, with inflation readings from the US and UK on the horizon, which could drive equity market sentiment during the remainder of the week.

Read more
12 Feb 2024 07:21

GSK gets FDA fast track for chronic hepatitis B treatment

(Sharecast News) - GSK announced on Monday that bepirovirsen, an investigational antisense oligonucleotide (ASO) aimed at treating chronic hepatitis B (CHB), had been granted fast track designation by the US Food and Drug Administration (FDA).

Read more
9 Feb 2024 09:15

LONDON BROKER RATINGS: Deutsche Bank cuts AstraZeneca to 'sell'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
6 Feb 2024 08:51

TOP NEWS: GSK reports positive news on trio of high profile products

(Alliance News) - GSK PLC on Tuesday delivered a triple dose of positive updates on some of its leading products, Arexvy, Shingrix and Blencep.

Read more
6 Feb 2024 07:47

LONDON BRIEFING: BP promises buyback despite drop in profit

(Alliance News) - Stocks in London are called to open higher, ahead of a slew of construction purchasing managers' index readings from the eurozone, the UK and Germany.

Read more
6 Feb 2024 07:23

GSK reports positive myeloma trial results, progresses vaccine applications

(Sharecast News) - GSK reported progress in its trial of a myeloma treatment on Tuesday, as well as regulatory progress around its shingles vaccine in China and its RSV vaccine in the United States.

Read more
1 Feb 2024 09:27

TOP NEWS: GSK maintains "vigorous" defence after settling Zantac case

(Alliance News) - GSK PLC on Thursday insisted upon its scientific integrity, after reaching another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
1 Feb 2024 09:11

GSK settles Zantac case in California without admitting liability

(Sharecast News) - GSK announced on Thursday that it had reached a confidential settlement to effectively resolve the legal case over Zantac filed in a California state court.

Read more
1 Feb 2024 09:03

LONDON BROKER RATINGS: Barclays cuts Next; JPMorgan raises easyJet

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning:

Read more
1 Feb 2024 07:42

LONDON BRIEFING: Shell profit falls; announces USD3.5 billion buyback

(Alliance News) - Stocks in London are set to follow New York into the red, after the US Federal Reserve quashed hopes of a March cut to interest rates and ahead of the Bank of England interest rate decision.

Read more
31 Jan 2024 17:05

LONDON MARKET CLOSE: Stocks mixed hours before expected US Fed hold

(Alliance News) - Stock prices in London closed mixed on Wednesday in a trade-thinned day ahead of the US Federal Reserve interest rate decision this evening.

Read more
31 Jan 2024 15:49

London close: Stocks mixed ahead of US Fed, BoE decisions

(Sharecast News) - London's financial markets finished with mixed performance on Wednesday, with investors closing their wallets ahead of rate announcements from both the US Federal Reserve and the Bank of England.

Read more
31 Jan 2024 12:05

LONDON MARKET MIDDAY: FTSE 100 flat ahead of Federal Reserve decision

(Alliance News) - The FTSE 100 in London was flat heading into Wednesday afternoon, as the US Federal Reserve's latest interest rate decision edges closer, keeping equity market enthusiasm to a minimum.

Read more
31 Jan 2024 09:13

TOP NEWS: GSK profit up on Arexvy boost in 2023 but total payout down

(Alliance News) - GSK PLC reported an increase in profit and revenue for 2023 as revenue for HIV medicine had stable growth, amid optimism in the company's outlook.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.